liver disease
Resolution Therapeutics Raises £63.5M in Series B Funding
The firm will use the funding to begin a first-in-human trial of its autologous macrophage cell therapy in liver disease.
After Proof-of-Concept, Resolution Therapeutics' Liver Cirrhosis Cell Therapy to Enter Phase I/II
Premium
Data on a non-engineered version of the macrophage cell therapy has given the Edinburgh spinout confidence as it moves forward with an engineered version.
Kriya Therapeutics Acquires Gene Therapy Developer for FGF21 Assets
Kriya expects to begin clinical trials of Tramontane's lead FGF21 gene therapy in NASH by the first half of 2025.